Will add it to the watchlist, thanks

nmrd have all the ingredients for a super squeeze low float .real business. Heavily shorted buy and hold for me to multiple dollars. Next game maybe .

NMRD delisted from the Nasdaq to the OTC. **PPS closed at .12

https://otce.finra.org/otce/dailyList?viewType=Additions

NMRD new 52 week low

NMRD new 52 week low

NMRD new 52 week low

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

Date: September 13, 2023

LOUGHBOROUGH, Sep. 13, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program.

The primary objective of the study was to establish whether a metabolic program with a daily wear CGM worn twice a month resulted in greater engagement levels and sustainable weight reduction, and how this compared to other programs. The multi-centered study was run in collaboration with the UK’s National Health Service.

Known as Miboko (Mind, Body, Konnect), the program is the first to integrate a daily-wear and non-invasive glucose sensor with the Company’s bespoke app, educational content and AI driven analytics platform.

Users were invited to participate by their primary care practice, based on a BMI over 25. None of those invited to participate had expressed a willingness to join a metabolic weight loss program or had previously heard of the Miboko program. Participants used the Miboko app, and were given access to relevant education modules relating to aspects of metabolic health and weight loss. Diet and lifestyle were entered daily into the app, and weight was recorded weekly. Every two weeks, users wore the daily wear continuous glucose sensor, which tracked and displayed real-time glucose. At the end of the day, participants were provided with a MetascoreÒ and measure of glucose variability.

In addition, users were presented with a video report which analysed their glucose trends and made diet and lifestyle recommendations. The MetascoreÒ is derived from a number of factors including BMI, insulin sensitivity and lifestyle.

The study tracked 83 participants, with a mean age of 54 years old. The cohort was made up of 67% female (F), and 33% male (M), and 88% of participants recorded their ethnicity as ‘White’. After 20 weeks of enrolment, 59 people (16M/43F) had recorded weight loss, with 21 participants losing over 5KG (11 pounds). On an average basis, weight loss was 2.9KG (6.3 pounds) (1.9M/3.2F), with the rate of change increasing after week 8.

Qualitative feedback from users demonstrated substantially increased levels of understanding and empowerment on their weight loss goals, correlating to long-term behavioural changes that are pivotal to sustained weight loss. Of particular note is that users derived considerable benefit from their personalised insights, based on their MetascoreÒ and response to diet and exercise. Verbatims from users confirmed that CGM sensor use increased user participation, better understanding of food choices and portion size.

After 20 weeks of use, the program had a retention rate of 32.5%. When active participants were asked whether they would continue with the program, 64% of respondents stated they were likely or very likely to continue to use the program. This far exceeds retention rates for health and wellbeing apps of 16.7% at 13 weeks and 6.9% at 26 weeks.1

Published studies report that affordability is a key barrier to CGM adoption, and the Company aims to price its CGM-embedded program significantly lower than any presently available comparable program.

The integration of Nemaura’s CGM sensor means that for the first time, a low-cost metabolic health improvement prevention program will soon be commercially available. The Company has the advantage of its own proprietary non-invasive sensor technology, which significantly reduces sensor costs, as the sensors are only worn a few days each month.

The Company plans to publish more detailed results in due course. A link to the Miboko website can be found here: https://miboko.com

About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercialising non-invasive wearable diagnostic devices. The Company is currently also commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. Food and Drug Administration (the “FDA”). proBEAT™ combines non-invasive glucose data processed using artificial intelligence as part of a lifestyle program that is being refined for commercial launch.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

https://ih.advfn.com/stock-market/NASDAQ/nemaura-medical-NMRD/stock-news/92031388/form-8-k-current-report

$NMRD

NMRD new 52 week low

Nice pop

Up from here!

$NMRD About Nemaura Medical, Inc. - Nemaura Medical Inc. is a medical technology company developing and commercialising noninvasive wearable diagnostic devices. The company is currently commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service that has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Nice green close yesterday and a continuation today, with a new high of the day on the ASK. $NMRD

$NMRD closing green!

$NMRD trading just under 80% of its average volume in Power Hour...UP almost 10% and a nice chart uptrend!

$NMRD @Nasdaq Conference News: Neumara Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference #Diagnostics #DiabetesManagement #WearableTech #MicroCapRodeo #Chicago https://t.co/6irEjQtxa1

$NMRD trading low volume compared to its average volume in Power Hour... BUT UP almost 5%.

Good to see the official announcement from NMRD today on the company's important opportunity to present its diagnostic products and latest developments to a large, industry targeted audience base coming up next week.

Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference. The conference is being held on October 12 - 13, 2022 at the Swissotel Chicago.

Presentation Date: October 12, 2022

Time: 1:00 pm CT

Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference. To schedule a meeting, please email angie.wright@issuerdirect.com

To register for the conference, click here: https://microcaprodeo.com/signup

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R)diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one's overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit http://www.NemauraMedical.com.

Contact:

Jules Abraham

CORE IR

917-885-7378

julesa@coreir.com

Looking forward to some new exposure for $NMRD.

$NMRD time to load up!

That conference is huge each year. This is great news. no wonder the bullish accumulation! $NMRD

$NMRD news out: Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference https://finance.yahoo.com/news/nemaura-medical-present-microcap-rodeo-120000238.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

Yup, and green as we start Power Hour. Looking good $NMRD.

2.10's super thin now!

$NMRD

Huge volume on Friday and today it's been quiet... Let's see if it can close above $2.

$NMRD 60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago https://finance.yahoo.com/news/60-companies-present-2nd-annual-130500351.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$NMRD +15.65% closing the week strong!

$NMRD trading 3.5x over its 10-day average volume...UP almost 19%. Looking like some loading happening today.

A global investor audience will open Nemaura’s Diabetes Management Solution, BEATdiabetes to U.S. and potentially global sales and marketing investment. $NMRD

$NMRD Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S. https://www.globenewswire.com/news-release/2022/09/27/2523249/0/en/Nemaura-and-EVERSANA-sign-preliminary-agreement-for-large-scale-launch-of-Nemaura-s-Diabetes-Management-Program-in-the-U-S.html

NMRD should gain significant exposure for its advancements in wearable diagnostic technology at the upcoming Windy City Conference in just a couple of weeks. With the large number of high level participants this event is a great opportunity to reach a lot of the investment community all in one place.

60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago https://www.accesswire.com/717535/60-Companies-to-Present-at-the-2nd-Annual-MicroCap-Rodeo--Windy-City-Roundup-Conference-on-October-12th--13th-2022-in-Chicago

RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor audience.

The conference begins on Tuesday, October 12th, 2022, with company presentations beginning at 9:00 am Central Time. In addition to the live presentations, they will be shared via webcast. 1x1 Meetings are being held on Wednesday and Thursday all day during the conference as well.

Join us for a full two days of presentations. A preliminary agenda is located here: https://microcaprodeo.com/agendaIf you would like to attend and participate in the 2nd Annual MicroCap Rodeo: Windy City Roundup Conference, please register here and book 1x1 meetings with presenting companies: https://microcaprodeo.com/signup

Full event website: https://microcaprodeo.com/

Looking forward to seeing how $NMRD and EVERSANA expand this relationship...

The agreement covers the U.S. and all global sales and marketing of Nemaura’s Diabetes Management Solution, BEATdiabetes. The BEATdiabetes program is based on Nemaura’s noninvasive glucose monitoring solution, proBEAT. Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers.

$NMRD looking good today, trading nearly 80% of its 10-day average volume as we head into the last 30 minutes of the day... UP almost 9%.

$NMRD 60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago https://finance.yahoo.com/news/60-companies-present-2nd-annual-130500351.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance
$ATXI $MULN $APRN $LVWR $ILUS $OWUV $INTK

$1.78s hit and $NMRD is consolidating as lunchtime starts... Power Hour should be interesting.

Great News today... $NMRD trading over 70% of its 10-day average volume as lunchtime starts...UP over 10%!

1.78's thin on the ask!

$NMRD

Excellent news from NMRD today on their new agreement with EVERSANA Life Sciences for widespread marketing of the Nemaura Medical product line to reach many more people around the world who are in need of advanced personal health monitoring technology. Be sure to check out the EVERSANA company website at the link below which offers a lot of detail on this company's market positioning and capabilities.
-----------------------------------------------------------------------------------------------------
EVERSANA(TM) is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

To learn more about EVERSANA, visit http://www.eversana.com or connect through LinkedIn and Twitter.

$NMRD Jim Lang, Chief Executive Officer of EVERSANA, added, “Nemaura’s innovative programs and sensor technology potentially represent a major change in the way in which diabetes is addressed and how patients may be supported. We look forward to leveraging our full suite of commercialization services to support a successful U.S. launch.”

NEWS: Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.
September 27, 2022 08:00 ET | Source: Nemaura Medical, Inc

CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it has entered into a preliminary agreement with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry.

The agreement covers the U.S. and all global sales and marketing of Nemaura’s Diabetes Management Solution, BEATdiabetes. The BEATdiabetes program is based on Nemaura’s noninvasive glucose monitoring solution, proBEAT. Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers.

In early pilot trials conducted over the last 12 months, the BEATdiabetes program yielded overall positive outcomes, demonstrating that sustainable, long-term weight loss and, therefore, improvement in the management of Type 2 diabetes is achievable. Incumbents in the space have also demonstrated clinically significant outcomes when such diabetes management programs are used in conjunction with continuous glucose monitors. Nemaura, however, has the advantage of its own proprietary noninvasive sensor technology which significantly reduces sensor costs, as the sensors are only worn a few days each month.

EVERSANA is widely regarded as the leader in digital therapeutic commercialization. Across the life sciences industry, the fully integrated commercialization provider works with more than 670 organizations, including innovative start-ups and established pharmaceutical companies.

Dr. Faz Chowdhury, Nemaura Medical’s Chief Executive Officer, stated, “We are excited to be working with EVERSANA to bring our diabetes management solution to market. This is a culmination of several months of negotiations with EVERSANA following the encouraging outcome of the pilot studies. Diabetes management is an area of huge unmet need, and we anticipate that our solution will be very easy, simple to administer, and highly cost-effective, all elements supporting large-scale adoption.”

Jim Lang, Chief Executive Officer of EVERSANA, added, “Nemaura’s innovative programs and sensor technology potentially represent a major change in the way in which diabetes is addressed and how patients may be supported. We look forward to leveraging our full suite of commercialization services to support a successful U.S. launch.”

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercialising noninvasive wearable diagnostic devices. The company is currently commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service that has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

About EVERSANA™

EVERSANA™ is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

Media Contacts

Jules Abraham
CORE IR
+1 917-885-7378

EVERSANA
Matt Braun
Director, Corporate Communications
matt.braun@eversana.com
+1 414-434-4830

Some other $NMRD highlights include...

*Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited (“MSWL”)
*Signed a global commercial contract with MySugarWatch DuoPack Limited.

NMRD is addressing some of the most pressing needs on the field of personal medical device monitoring. The company is focused on key issues including all of the following:

Real-Time Glucose measurements and Trend Data Which May Help with Diabetes and pre-Diabetes.

Non-Invasive Glucose Data Processed via Artificial Intelligence and Digital Healthcare Subscription Service.

Program to Understand How Certain Foods and Lifestyle Habits can Impact Metabolic Health and well-being.

$NMRD Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

Epic Fail...Dead no volume and 62 week lows...

$NMRD has funds to be used as needed to grow their revenues in the coming quarters...

Company entered into a new note purchase agreement in May 2022 and received $5 million in proceeds

"Importantly, given the current market climate, we are extremely pleased to have recently raised additional non-dilutive funding without any attached warrants or options, further strengthening our balance sheet as we anticipate growing our revenues in the coming quarters.”

NMRD certainly does have very high earnings potential with the company's advanced wearable diagnostic products that are applicable to the $50+ billion diabetes market today. The need for this kind of non-invasive and convenient diagnostic monitoring solution will only continue to grow in the years ahead.
----------------------------------------------------------------------------------------------------------

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT and proBEAT. sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEATdiabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one's overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

Huge upside here, watching for updates!

$NMRD

proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

$NMRD

$NMRD "Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023."

For more information, please visit www.NemauraMedical.com

That beta trial updates are expected soon Bud! $NMRD

$NMRD consolidation after its run over $2.30...